Value Assessment of Orphan Drugs in Switzerland and the EU

31 Oct, 2018

The Rare Disease Action Forum holds an international event on the topic of “value assessment of orphan drugs in Switzerland and the EU” on 31 October 2018 in Basel, Switzerland Experts from authorities, patient organizations and the industry will provide insights to assessment models for orphan drugs in Switzerland, the EU and specific individual countries such as Germany, Austria and France.

A timely and predictable value assessment process for orphan drugs plays an important role in enabling access to treatment for patients with rare diseases. Due to the characteristics of rare diseases and related clinical trials (e.g. very low patient numbers, no active comparator) standard value assessment processes are especially challenging for orphan drugs. An additional hurdle to the reimbursement and access for patients is imposed by the fact that value assessments are mostly conducted at the time of marketing authorization without consideration of growing evidence from use in clinical practice.

The RDAF event will give participants the opportunity to exchange knowledge and best practices on this topic.

13th International Rare Disease Day in Switzerland

The Rare Disease Action Forum supports the International Rare Disease Day, a globally coordinated movement that advocates for equal access to healthcare, treatments and diagnoses for patients with rare diseases, which takes place on 28 February. Watch the Rare Disease...

The RDAF organizes a webinar on early diagnosis for rare diseases in Switzerland

The Rare Disease Action Forum (RDAF) will host a multi-stakeholder webinar on ‘Early diagnosis for rare diseases’ on 29 March 2023, 17.00-18.30 CET. The webinar focuses on the diagnosis of rare diseases in Switzerland, provides an overview of the related challenges,...